HPS Trailer Page
for
WEST

UserID: bli

Printer: cm1_8e12_gbelptr

Summary

Document	Pages	Printed	Missed
WO009730693	30	30	0
Total (1)	30	30	0

US-CL-CURRENT: 514/723; 525/88, 525/89, 525/93, 568/624

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 3. Document ID: US RE37285 E

L2: Entry 3 of 18 File: USPT Jul 17, 2001

US-PAT-NO: RE37285
DOCUMENT-IDENTIFIER: US RE37285 E

TITLE: Polyoxypropylene/polyoxyethylene copolmers with improved biological activity

DATE-ISSUED: July 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Emanuele; R. Martin	Alpharetta	GA		
Hunter; Robert L.	Bellaire	TX		
Culbreth; Paula H.	Loganville	GA		

US-CL-CURRENT: 514/723

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 4. Document ID: US 6149922 A

L2: Entry 4 of 18 File: USPT Nov 21, 2000

US-PAT-NO: 6149922
DOCUMENT-IDENTIFIER: US 6149922 A

method for making

TITLE: Vaccine adjuvant and vaccine

DATE-ISSUED: November 21, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Balasubramanian; Mannarsamy	Roswell	GA		
Newman; Mark Joseph	Duluth	GA		
Emanuele; R. Martin	Alpharetta	GA		
Rivera-Marrero; Carlos A.	Norcross	GA		
Todd; Charles William	Lawrenceville	GA		
Brey, III; Robert Newton	Alpharetta	GA		

US-CL-CURRENT: 424/280.1; 424/278.1, 424/279.1, 424/283.1, 514/723, 514/772.3, 568/624

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 5. Document ID: US 6086899 A

L2: Entry 5 of 18 File: USPT Jul 11, 2000

US-PAT-NO: 6086899
DOCUMENT-IDENTIFIER: US 6086899 A

TITLE: Vaccine adjuvant and vaccine

102(e) did

DATE-ISSUED: July 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Balasubramanian; Mannarsamy	Roswell	GA		
Newman; Mark Joseph	Duluth	GA		
Emanuele; R. Martin	Alpharetta	GA		
Rivera-Marrero; Carlos A.	Norcross	GA		
Todd; Charles William	Lawrenceville	GA		
Brey, III; Robert Newton	Alpharetta	GA		

US-CL-CURRENT: 424/280.1; 424/278.1, 424/283.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 6. Document ID: US RE36665 E

L2: Entry 6 of 18 File: USPT Apr 18, 2000

US-PAT-NO: RE36665
DOCUMENT-IDENTIFIER: US RE36665 E

TITLE: Polyoxypropylene/polyoxyethylene copolymers with improved biological activity

DATE-ISSUED: April 18, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Emanuele; R. Martin	Alpharetta	GA		
Hunter; Robert L.	Bellaire	TX		
Culbreth; Paula H.	Loganville	GA		

US-CL-CURRENT: 568/624

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 7. Document ID: US 5990241 A

L2: Entry 7 of 18 File: USPT Nov 23, 1999

US-PAT-NO: 5990241
DOCUMENT-IDENTIFIER: US 5990241 A

TITLE: Polyoxypropylene/polyoxyethylene copolymers with improved biological activity

method of making
no antigen

DATE-ISSUED: November 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Emanuele; R. Martin	Hillbrook	GA		
Hunter; Robert L.	Tucker	GA		
Culbreth; Paula H.	Loganville	GA		

US-CL-CURRENT: 525/88; 525/89, 525/93, 568/624

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 8. Document ID: US 5811088 A

L2: Entry 8 of 18 File: USPT Sep 22, 1998

US-PAT-NO: 5811088
DOCUMENT-IDENTIFIER: US 5811088 A

PA

with chemical drugs

TITLE: Antiinfective compounds and methods of use

DATE-ISSUED: September 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hunter; Robert L.	Tucker	GA		
Emanuele; R. Martin	Alpharetta	GA		
Allaudeen; Hameedsulthan S.	Alpharetta	GA		

US-CL-CURRENT: 424/78.08; 424/78.17

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 9. Document ID: US 5776891 A

L2: Entry 9 of 18 File: USPT Jul 7, 1998

US-PAT-NO: 5776891
DOCUMENT-IDENTIFIER: US 5776891 A

method of making

TITLE: Compositions for reducing multidrug resistance

DATE-ISSUED: July 7, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coon; John S.	Oak Park	IL		
Balasubramanian; Mannarsamy	Roswell	GA		
Emanuele; R. Martin	Alpharetta	GA		
Shah; Himanshu	Atlanta	GA		

US-CL-CURRENT: 514/10; 514/183, 514/283, 514/34, 514/35, 514/411, 514/506, 514/515, 514/765, 514/950

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 10. Document ID: US 5696298 A

L2: Entry 10 of 18 File: USPT Dec 9, 1997

US-PAT-NO: 5696298
DOCUMENT-IDENTIFIER: US 5696298 A

TITLE: Polyoxypropylene/polyoxyethylene copolymers with improved biological activity

DATE-ISSUED: December 9, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Emanuele; R. Martin	Alpharetta	GA		
Hunter; Robert L.	Tucker	GA		
Culbreth; Paula H.	Loganville	GA		

US-CL-CURRENT: 568/623; 568/624

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

Generate Collection | Print

Terms	Documents
Emanuele R Martin.in.	18

Display Format: CIT Change Format

Previous Page Next Page

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 10 of 18 returned.

PTO 102(e)

☐ 1. Document ID: US 6416947 B1

L2: Entry 1 of 18 File: USPT Jul 9, 2002

US-PAT-NO: 6416947
DOCUMENT-IDENTIFIER: US 6416947 B1

TITLE: Vaccine adjuvant and vaccine method

DATE-ISSUED: July 9, 2002

102(e) parental case 08/086,899 already in 102(e) rejection.

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Balasubramanian; Mannarsamy	Roswell	GA		
Newman; Mark Joseph	Duluth	GA		
Emanuele; R. Martin	Alpharetta	GA		
Rivera-Marrero; Carlos A.	Norcross	GA		
Todd; Charles William	Lawrenceville	GA		
Brey, III; Robert Newton	Alpharetta	GA		

US-CL-CURRENT: 435/5; 424/278.1, 424/280.1, 424/283.1, 528/421

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 2. Document ID: US 6359014 B1

L2: Entry 2 of 18 File: USPT Mar 19, 2002

US-PAT-NO: 6359014
DOCUMENT-IDENTIFIER: US 6359014 B1

TITLE: Polyoxypropylene/polyoxyethylene copolymers with improved biological activity

DATE-ISSUED: March 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Emanuele; R. Martin	Alpharetta	GA		
Hunter; Robert L.	Tucker	GA		
Culbreth; Paula H.	Loganville	GA		

WEST

End of Result Set

Generate Collection Print

L1: Entry 1 of 1 File: USPT Jun 4, 1996

US-PAT-NO: 5523492
DOCUMENT-IDENTIFIER: US 5523492 A

TITLE: Polyoxypropylene/polyoxyethylene copolymers with improved biological activity

DATE-ISSUED: June 4, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Emanuele; R. Martin	Alpharetta	GA		
Hunter; Robert L.	Tucker	GA		
Culbreth; Paula H.	Loganville	GA		

US-CL-CURRENT: 568/624

CLAIMS:

We claim:

1. A polyoxypropylene/polyoxyethylene block copolymer with the following general formula:

HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H

wherein a is an integer such that the molecular weight represented by the polyoxypropylene portion of the copolymer is between approximately 900 and 15000 Daltons and b is an integer such that the molecular weight represented by the polyoxyethylene portion of the copolymer constitutes between approximately 5% and 90% of the copolymer and the polydispersity value is less than approximately 1.07.

2. The block copolymer of claim 1, wherein the polydispersity value is less than approximately 1.05.

3. The block copolymer of claim 1, wherein the polydispersity value is less than approximately 1.03.

4. The block copolymer of claim 1, wherein the copolymer is substantially free of unsaturation.

5. The block copolymer of claim 1, wherein the copolymer has a molecular weight range of between approximately 1,200 and 6500 daltons.

6. The block copolymer of claim 5, wherein the polyoxyethylene portion of the copolymer constitutes between approximately 10% and 90% of the

copolymer.

7. A surface-active copolymer comprising a polyoxypropylene/polyoxyethylene block copolymer with the following general formula:

HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H

wherein a is an integer such that the molecular weight of the hydrophobe (C.sub.3 H.sub.6 O) is approximately 1750 daltons and b is an integer such that the average total molecular weight of the compound is approximately 8400 daltons and the polydispersity value is less than approximately 1.07.

8. The surface-active copolymer of claim 7, wherein the polydispersity value is less than approximately 1.05.

9. The surface-active copolymer of claim 7, wherein the polydispersity value is less than approximately 1.03.

10. The surface-active copolymer of claim 7, wherein the copolymer is substantially free of unsaturation.

11. A surface-active copolymer comprising a polyoxypropylene/polyoxyethylene block copolymer with the following general formula:

HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H

wherein the total molecular weight of the copolymer is between approximately 5,000 and 15,000 daltons and b is an integer such that the molecular weight represented by the polyoxyethylene portion of the copolymer constitutes between approximately 75% and 85% of the copolymer.

12. The surface-active copolymer of claim 11, wherein the total molecular weight of the copolymer is between approximately 7,000 and 12,000 daltons.

13. The surface-active copolymer of claim wherein the copolymer is substantially free of unsaturation.

14. A surface-active copolymer comprising a polyoxypropylene/polyoxyethylene block copolymer with the following general formula:

HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H

wherein a is an integer such that the molecular weight of the hydrophobe (C.sub.3 H.sub.6 O) is approximately 9,700 daltons and the average total molecular weight of the compound is approximately 10,000 daltons and the polydispersity value is less than approximately 1.07.

15. The surface-active copolymer of claim 14, wherein the polydispersity value is less than approximately 1.05.

16. The surface-active copolymer of claim 14, wherein the polydispersity value is less than approximately 1.03.

17. The surface-active copolymer of claim 14, wherein the copolymer is substantially free of unsaturation.

18. A surface-active copolymer comprising a polyoxypropylene/polyoxyethylene block copolymer with the following general formula:

HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4

O).sub.b H

wherein a is an integer such that the molecular weight of the hydrophobe (C.sub.3 H.sub.6 O) is approximately 3400 daltons and the average total molecular weight of the compound is approximately 4000 daltons and the polydispersity value is less than approximately 1.07.

19. The surface-active copolymer of claim 18, wherein the polydispersity value is less than approximately 1.05.

20. The surface-active copolymer of claim 18, wherein the polydispersity value is less than approximately 1.03.

21. The surface-active copolymer of claim 18, wherein the copolymer is substantially free of unsaturated.

22. Substantially pure block copolymer having the formula

HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H

wherein a is an integer such that the molecular weight of the hydrophobe (C.sub.3 H.sub.6 O) is approximately 1750 Daltons and b is an integer such that the average molecular weight of the compound is approximately 8400 Daltons, the block copolymer having a polydispersity value of less than approximately 1.07.

23. The block copolymer of claim 22, wherein the polydispersity value is less than approximately 1.05.

24. The block copolymer of claim 22, wherein the polydispersity value is less than approximately 1.03.

25. The block copolymer of claim 22, wherein the copolymer is substantially free of unsaturation.

26. Substantially pure block copolymer having the formula

HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H

wherein a is an integer such that the molecular weight of the hydrophobe (C.sub.3 H.sub.6 O) is approximately 1750 Daltons and the average molecular weight of the compound is approximately 8400 Daltons, and wherein the block copolymer comprises at least 92.2 percent by weight of a middle molecular weight fraction, not more than 2.1 percent by weight of an early molecular weight fraction, and not more than 5.7 percent by weight of a late molecular weight fraction when fractionated by gel permeation chromatography.

27. The block copolymer of claim 26, wherein the copolymer is substantially free of unsaturation.

28. The block copolymer of claim 26, wherein the copolymer comprises essentially 100 percent of the middle molecular weight fraction.

supplimental search
more search is conducted
with parental case
09/600,084

```
=> "Fluronic F27"
             6 "FLURONIC"
            42 "F27"
L1           0 "FLURONIC F27"
                 ("FLURONIC"(W)"F27")

=> fluronic and chitosan
             6 FLURONIC
         13148 CHITOSAN
           681 CHITOSANS
         13169 CHITOSAN
                 (CHITOSAN OR CHITOSANS)
L2           0 FLURONIC AND CHITOSAN

=> "fluronic F127"
             6 "FLURONIC"
           399 "F127"
L3           0 "FLURONIC F127"
                 ("FLURONIC"(W)"F127")

=> F127 and Chitosan
           399 F127
         13148 CHITOSAN
           681 CHITOSANS
         13169 CHITOSAN
                 (CHITOSAN OR CHITOSANS)
L4          10 F127 AND CHITOSAN

=> D L4 IBIB TI SO AU ABS 1-10

L4   ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:        2002:658574  CAPLUS
DOCUMENT NUMBER:         137:190763
TITLE:                   Polymer-based compositions for treatment of mucositis
INVENTOR(S):             Rosenthal, Gary J.; Etter, Jeffrey B.; Rodell,
Timothy
                         C.; Schauer, Wren H.; Samaniego, Adrian
PATENT ASSIGNEE(S):      USA
SOURCE:                  U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S.
                         Ser. No. 721,516.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  2
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.   DATE
     ---------------   ----  --------       ---------------   --------
     US 2002119104      A1   20020829       US 2001-993383    20011121
PRIORITY APPLN. INFO.:                   US 2000-721516   A2 20001122
TI   Polymer-based compositions for treatment of mucositis
SO   U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 721,516.
     CODEN: USXXCO
IN   Rosenthal, Gary J.; Etter, Jeffrey B.; Rodell, Timothy C.; Schauer, Wren
     H.; Samaniego, Adrian
AB   A therapeutic compn. useful for treatment of a mucositis at a mucosal
site
     comprises a pharmaceutical substance effective for treating mucositis
     formulated with a biocompatible polymer, such as a biocompatible
```

reverse-thermal gelation polymer. The pharmaceutical substance is selected from an antibacterial, an anti-inflammatory, an antioxidant, an anesthetic, an analgesic, a protein, a peptide and a cytokine. For example, 10% of the antioxidant, N-acetyl-L-cysteine, was formulated in an aq. delivery matrix contg. 16.25% Pluronic **F127** and 0.57M NaOH (pH 4-5). The formulation reduced the mean clin. mucositis scores relative to the vehicle and water controls in a hamster radiation-induced oral mucositis model.

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:408476 CAPLUS
DOCUMENT NUMBER: 136:406863
TITLE: Treatment of mucositis
INVENTOR(S): Rosenthal, Gary J.; Etter, Jeffrey B.; Rodell, Timothy C.; Schauer, Wren H.; Samaniego, Adrian
PATENT ASSIGNEE(S): RxKinetix, Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002041837	A2	20020530	WO 2001-US44186	20011121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-721516 A 20001122
TI Treatment of mucositis
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
IN Rosenthal, Gary J.; Etter, Jeffrey B.; Rodell, Timothy C.; Schauer, Wren H.; Samaniego, Adrian
AB This present invention provides a therapeutic compn. for use in the treatment of mucositis and a method for using such a therapeutic compn. The therapeutic compn. includes a pharmaceutical effective for treating mucositis formulated with a biocompatible polymer, such as a biocompatible reverse-thermal gelation polymer. The antioxidant, N-acetyl-L-cysteine (NAC), was formulated in delivery matrixes by mixing the following components under sterile conditions: N-acetycysteine 10, Pluronic **F127** 16.25, and **chitosan** 0.5%, and 0.57M NaOH soln. NAC formulations reduced the mean clin. mucositis scores relative to the vehicle and water controls, with the NAC formulated in Pluronic **F127** being the most effective.

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:900424 CAPLUS
DOCUMENT NUMBER: 137:77483
TITLE: ProJuvant (Pluronic **F127**.RTM./

chitosan) enhances the immune response to intranasally administered tetanus toxoid

AUTHOR(S): Julie Westerink, M. A.; Louise Smithson, S.; Srivastava, Neeti; Blonder, Joan; Coeshott, Claire; Rosenthal, Gary J.

CORPORATE SOURCE: Department of Medicine, Medical College of Ohio, Toledo, OH, 43614, USA

SOURCE: Vaccine (2001), 20(5-6), 711-723
CODEN: VACCDE; ISSN: 0264-410X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

TI ProJuvant (Pluronic **F127**.RTM./**chitosan**) enhances the immune response to intranasally administered tetanus toxoid

SO Vaccine (2001), 20(5-6), 711-723
CODEN: VACCDE; ISSN: 0264-410X

AU Julie Westerink, M. A.; Louise Smithson, S.; Srivastava, Neeti; Blonder, Joan; Coeshott, Claire; Rosenthal, Gary J.

AB The potential to generate both a systemic and local immune response makes the mucosal system an attractive site for immunization. However, mucosal administration of protein and peptide antigens generally results in a poor immune response. Successful mucosal vaccination is therefore largely dependent on the development of effective mucosal adjuvants. In this study we have examd. the effect of mucosal administration of tetanus toxoid (TT) in the presence of a non-ionic block copolymer, Pluronic.RTM. **F127** (**F127**), with **chitosan** or lysophosphatidylcholine (LPC) on the systemic and mucosal immune response.
Balb/c mice, immunized i.p. with TT and boosted intranasally (i.n.) with TT in **F127**/**chitosan**, demonstrated a significant enhancement in the systemic anti-TT antibody response compared to mice boosted i.n. with TT in PBS or mice boosted i.n. with TT in **F127**/LPC. We detd. the antigen specific IgA response in the nasal and lung washes of these animals and found a significant increase in anti-TT mucosal IgA response in the group boosted with TT in **F127**/**chitosan**. Similarly, mice immunized and boosted i.n. with TT in **F127**/**chitosan** had a significant enhancement of their systemic anti-TT IgG and mucosal IgA antibody responses compared to the animals immunized and boosted i.n. with TT in PBS or TT in **F127**/LPC. The results of these studies suggest that **F127**/**chitosan** represents a novel mucosal vaccine delivery system, consisting of two components, that appear to exert an additive or synergistic effect on the immune response.

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:338373 CAPLUS

DOCUMENT NUMBER: 134:357564

TITLE: Protease inhibitors as modulators of periodontal wound healing

INVENTOR(S): Xiao, Yin; Bartold, Peter Mark; Bunn, Clive Leighton; Sharp, Phillip John

PATENT ASSIGNEE(S): Biotech Australia Pty Limited, Australia; The University of Queensland

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032203	A1	20010510	WO 2000-AU1342	20001102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1227835	A1	20020807	EP 2000-972470	20001102
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: AU 1999-3806 A 19991102
WO 2000-AU1342 W 20001102

TI Protease inhibitors as modulators of periodontal wound healing
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
IN Xiao, Yin; Bartold, Peter Mark; Bunn, Clive Leighton; Sharp, Phillip John
AB The invention relates to methods for regulating periodontal tissue formation, particularly periodontal tissue attachment, utilizing plasminogen activator inhibitors or functional derivs., equiv., homologues, analogs or mimetics thereof are described. Further, the invention provides methods for the therapeutic and/or prophylactic treatment of conditions necessitating the up-regulation, inducement or other enhancement of periodontal wound healing such as gingivitis, periodontitis or following gum injuries, and compns. suitable for use in said methods. Efficacy of plasminogen activator inhibitor 2 in (PAI-2) periodontal wound healing is shown. A topical gel contained hydroxyethyl cellulose 1.8, propylene glycol 10, polysorbate-80 0.02%, and PAI-2 50 g/mL.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:741892 CAPLUS
DOCUMENT NUMBER: 133:313639
TITLE: Pharmaceutical formulations comprising bisphosphonates and additive agents providing enhanced absorptions of the bisphosphonates
INVENTOR(S): Lindfors, Lennart; Lofroth, Jan-Erik; Sjogren, Sven; Ungell, Anna-Lena
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061111	A1	20001019	WO 2000-SE664	20000406
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1171097	A1	20020116	EP 2000-921288	20000406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 2001004895	A	20011210	NO 2001-4895	20011008

PRIORITY APPLN. INFO.: SE 1999-1272 A 19990409
WO 2000-SE664 W 20000406

OTHER SOURCE(S): MARPAT 133:313639

TI Pharmaceutical formulations comprising bisphosphonates and additive agents
providing enhanced absorptions of the bisphosphonates

SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2

IN Lindfors, Lennart; Lofroth, Jan-Erik; Sjogren, Sven; Ungell, Anna-Lena

AB The present invention provides pharmaceutical formulations comprising at least one bisphosphonate and an additive consisting of one or more absorption enhancing agents. The said pharmaceutical formulations are useful for the inhibition of bone resorption and for the treatment and prevention of osteoporosis. A compn. contg. alendronate 2.3, caprylic acid sodium salt 11.5 mg, and 50 mM Tris with 100 mM NaCl 1 g was formulated.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:725733 CAPLUS
DOCUMENT NUMBER: 133:298044
TITLE: Viscosity-enhanced ophthalmic solutions having detergent action and their use on contact lenses
INVENTOR(S): Cantoro, Amalio
PATENT ASSIGNEE(S): Laboratoire Medidom S.A., Switz.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000060038	A1	20001012	WO 2000-IB388	20000331
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU,				

IE, SI, LT, LV, FI, RO
US 2002022055 A1 20020221 US 2000-511570 20000223
NO 2001004085 A 20011022 NO 2001-4085 20010822
PRIORITY APPLN. INFO.: US 1999-121424P P 19990223
WO 2000-CA175 W 20000223
TI Polymer compositions and methods for improving integrity of compromised body passageways and cavities
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
IN Signore, Pierre E.; Machan, Lindsay S.
AB The present invention provides compns. and methods for improving the integrity of body passageways following surgery or injury.
Representative
examples of therapeutic agents include microtubule stabilizing agents, fibrosis inducers, angiogenic factors, growth factors and cytokines and other factors involved in the wound healing or fibrosis cascade. Polymeric films of ethylene-vinyl acetate copolymer contg. paclitaxel and Pluronic **F127** were prepd. and the release of paclitaxel and property of the film was studied. The efficacy of the film in a vascular wound healing rat model was shown.

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:372055 CAPLUS
DOCUMENT NUMBER: 131:23522
TITLE: Compositions for nasal administration
INVENTOR(S): Illum, Lisbeth; Watts, Peter James
PATENT ASSIGNEE(S): Danbiosyst UK Limited, UK
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9927905	A1	19990610	WO 1998-GB3572	19981127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2312839	AA	19990610	CA 1998-2312839	19981127
AU 9912535	A1	19990616	AU 1999-12535	19981127
ZA 9810886	A	20000529	ZA 1998-10886	19981127
EP 1035833	A1	20000920	EP 1998-955814	19981127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001524509	T2	20011204	JP 2000-522892	19981127
NO 2000002851	A	20000602	NO 2000-2851	20000602
US 6342251	B1	20020129	US 2000-586139	20000602
US 2001046519	A1	20011129	US 2001-920698	20010801

PRIORITY APPLN. INFO.: GB 1997-25519 A 19971202
GB 1998-5253 A 19980313
WO 1998-GB3572 W 19981127
US 2000-586139 A1 20000602

TI Compositions for nasal administration
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
IN Illum, Lisbeth; Watts, Peter James
AB A compn. for the nasal delivery of a drug suitable for the treatment of erectile dysfunction to a mammal is adapted to provide an initial rise in plasma level followed by a sustained plasma level of the drug. Examples given were apomorphine in a pectin based formulation and a Pluronic **F127** formulation.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:594593 CAPLUS
DOCUMENT NUMBER: 127:239134
TITLE: Suppository composition of the drug which undergo the hepatic first pass effect
INVENTOR(S): Yoon, Sung June; Ryu, Jei Man; Choi, Han Gon; Jung, Jae Hee; Sung, Yong Kiel; Yoo, Jong Ho
PATENT ASSIGNEE(S): Dong Wha Pharmaceutical Industrial Co., Ltd., S. Korea
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9730693	A1	19970828	WO 1997-KR32	19970225

W: CA, CN, JP
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRIORITY APPLN. INFO.: KR 1996-4566 19960226
TI Suppository composition of the drug which undergo the hepatic first pass effect
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
IN Yoon, Sung June; Ryu, Jei Man; Choi, Han Gon; Jung, Jae Hee; Sung, Yong Kiel; Yoo, Jong Ho
AB A suppository compn. contains a drug which undergoes the hepatic first-pass effect, poloxamer, and hydrophilic natural polymers. The suppository compn. of this invention is characterized in that: has the gelation temp. of 30 to 36.degree., and is a liq. form at room temp., and readily becomes a gel at body temp. after rectal administration; has the remarkable gel strength, and is not leaked out the anus; has the remarkable bioadhesive force, and does not climb up to the end of the colon, therefore ensures better bioavailability of the drug. A suppository contained poloxamer F-127 15, poloxamer F-68 19, sodium alginate 0.2, propranolol 0.4, Me P-hydroxybenzoate 0.06, Pr p-hydroxybenzoate 0.03, and water q.s. 100 g. The suppository had a gelation temp. of 33.4.degree., and gel strength of 16.0 s.

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:347899 CAPLUS
DOCUMENT NUMBER: 125:95754
TITLE: Intranasal mucociliary clearance of putative bioadhesive polymer gels

AUTHOR(S): Zhou, Mengping; Donovan, Maureen D.
CORPORATE SOURCE: University of Iowa, College of Pharmacy, Iowa City, IA, 52242, USA
SOURCE: International Journal of Pharmaceutics (1996), 135(1,2), 115-125
CODEN: IJPHDE; ISSN: 0378-5173
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

TI Intranasal mucociliary clearance of putative bioadhesive polymer gels

SO International Journal of Pharmaceutics (1996), 135(1,2), 115-125
CODEN: IJPHDE; ISSN: 0378-5173

AU Zhou, Mengping; Donovan, Maureen D.

AB Rapid clearance of a drug away from the site of absorption is one factor that limits the bioavailability of compds. administered nasally. The effects of putative bioadhesive polymers including Me cellulose, sodium CM-cellulose, hydroxypropyl Me cellulose, **chitosan** glutamate, Carbopol 934P, PEG 600K and Pluronic **F127** on slowing nasal mucociliary clearance were investigated using a rat model. The clearance of these polymer gels from the nasal cavity was measured by following the removal of fluorescently labeled microspheres incorporated into the formulation. Due to the increased residence times of the gel formulations in the nasal cavity, the clearance rate of each polymer gel was slower than the clearance rate of a control microsphere suspension. The clearance rate consts. were in the range of 7-57% of the control clearance consts. Me cellulose gel (3%) resulted in the most prolonged nasal clearance whereas Carbopol 934P aq. gel (0.2%) had the most rapid clearance. A Carbopol 934P gel with propylene glycol and glycerol formal as cosolvents was prepd. to investigate the effect of an in situ gelling system on nasal clearance. The initial clearance of this cosolvent gel was not significantly different than the suspension, yet the total mass recovered was significantly lower than the control. The clearance of a 3% Me cellulose gel formulation from a damaged nasal mucosa was also investigated in order to obtain further information about the characteristics of nasal mucociliary clearance. From 4 h through the 7th day following the initial damage, although the initial clearance rate consts. were slightly higher, the time for 90% of the obsd. particle clearance was significantly extended and the total masses recovered were significantly lower than those obtained from a non-damaged mucosa.

TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

IT 1306123	B1	20010530	IT 1999-RM205	19990402
EP 1165731	A1	20020102	EP 2000-911192	20000331

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: IT 1999-RM205 A 19990402
WO 2000-IB388 W 20000331

TI Viscosity-enhanced ophthalmic solutions having detergent action and their use on contact lenses

SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2

IN Cantoro, Amalio

AB An ophthalmic soln. with viscosity-enhancing and detergent properties for contact lenses comprises one or more physiol. acceptable viscosity-enhancing agents in aq. soln. having a non-Newtonian rheol. behavior, and one or more physiol. acceptable nonionic surfactants. The nonionic surfactant may be selected among esters of fatty acids, sorbitan polyoxyethylates, or block polyoxyalkylenes. The viscosity-enhancing agent may be selected among hyaluronic acid or its salts with alkali or alk.-earth metals, ethers or esters of cellulose, **chitosans**, gellans, alginates or carboxyvinyl polymers. Examples were given which were based on Na hyaluronate and Pluronic **F127**.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:608560 CAPLUS
DOCUMENT NUMBER: 133:198740
TITLE: Polymer compositions and methods for improving integrity of compromised body passageways and cavities
INVENTOR(S): Signore, Pierre E.; Machan, Lindsay S.
PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050016	A2	20000831	WO 2000-CA175	20000223
WO 2000050016	A3	20010118		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1162956	A2	20011219	EP 2000-906091	20000223

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,